| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bd2a7184cc08c3acdcb4bf43c32c323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10afea640e3b96a7394c3c166cfa819b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0522384651ded87431b90e9b6909572d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9f5f2f2ab6ba0a4f705673802d1d562 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2003-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb707a8530525fbd69afb9225985600e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ebb205331672bb9bd2a3318389b4c29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0e6eeedac711f632cd22943cffd57dd |
| publicationDate |
2004-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004037282-A1 |
| titleOfInvention |
The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| abstract |
The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. . It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic agents comprising moieties showing binding affinity for CYP2W1 and moieties with cytotoxic/anti-cancer effect. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9988449-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9422358-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3291830-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007009816-A3 |
| priorityDate |
2002-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |